Updates from the American Society for Blood and Marrow Transplantation (ASBMT) Annual Meeting
Description: HOPA is pleased to present the second of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.
This BCOP webinar will highlight novel and innovative abstracts or presentations featured at the 2019 Transplantation and Cellular Therapy (TCT) Conference in Houston, TX. February 20-24, 2019. Research included in this module will focus on acute/chronic leukemia, myelodysplastic syndrome, and multiple myeloma patient populations undergoing allogeneic and autologous hematopoietic cell transplantation (HCT) or cellular therapy. Particularly, this presentation will focus on novel conditioning regimens, impact of post-HCT therapy and advances in treating graft versus host disease (GVHD).
- Discuss the relevant research on hematopoietic cell transplantation (HCT) or cellular therapies in acute/chronic leukemia, myelodysplastic syndrome, and multiple myeloma patients presented at the 2019 TCT meeting.
- Review novel research presented at the 2019 TCT on innovative approaches of conditioning regimens prior to allogeneic and autologous HCT.
- Evaluate the latest data on new approaches of treating graft versus host disease (GVHD) presented at the 2019 TCT meeting.
Katie Culos, PharmD BCOP
Dr. Culos is a Board Certified Oncology Pharmacist practicing since 2013 at Vanderbilt University Medical Center in Adult Cellular Therapy. She received her Doctorate of Pharmacy from the University of Illinois at Chicago College of Pharmacy and completed her Pharmacy Practice and Oncology Pharmacy Residency at University of Illinois Hospital & Health Sciences System. Outside of her clinical duties at Vanderbilt she serves as the Program Director of the Oncology Pharmacy Residency, works on the Antimicrobial and Immune Effector Cell Subcommittees and is the current past chair of the American Society of Bone Marrow Transplant Pharmacy Special Interest Group Research Working Committee.
Disclosure: Juno Therapeutics (A)(H); Incyte (A)(H); Jazz Pharmaceuticals (SP)(H)
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-064-H04-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by May 2, 2022.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% or greater is achieved. Tests must be completed by October 29, 2019.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
Individual webinar pricing:
HOPA Member Price: $40 / Non-Member Price: $70